Also in this playlist...
This transcript is automatically generated
All we don't want to tell you about a company.
That could very well become a major game changer for treating any genetic disease it's called -- an island in the ticker symbol of AIL and why.
Second quarter earnings release yesterday they did miss the street by five cents per share in net losses but.
If it's drugs make it to the open market and limitless joining me now in a Fox Business exclusive this -- president and C 00 very green.
And I was looking into Al asylum and this company the stock is up about eleven and a half percent -- for -- but that's almost.
Not nearly as support as important as what you do and the way it was described as silence saying that certain diseases.
A pretender telling just an average individual doesn't understand the stuff how does it work -- -- these therapies offering.
Sure -- and I think -- -- that's what we're trying to do it alone was -- an entirely new class of medicines based upon a breakthrough discovery biology -- -- interference.
And what we what we are looking to do is build Arnie I therapeutics that have an opportunity transformed disease and change the lives of patients.
By silencing disease causing genes as he said.
That because by genetics or by things we do -- ourselves like eat fatty foods or drink or -- smoke.
Well some of the diseases that it might be able to at least silence as you put it RSU which is of course a respiratory illness.
Liver cancer things like that TTR which attacks organs and tissues.
But yet it is not near getting -- a shelf or is it when would we see this out there because of course that's what analysts and investors would love to know how close are you -- So breakthrough discovery -- -- I really happen about a decade ago and over the last eight years we've made significant progress moving programs.
Into the clinic -- human.
Clinical trials to see how well works in patients so viral infection liver cancer.
-- to come Huntington's disease and as you mentioned.
A very important program treating -- specific form of -- -- doses TTR.
And my doses which is a genetic disease so even before we get to the market significant value can occur by showing.
-- -- -- -- -- Well names like Glaxo and Roche obviously believe this they've given you what 750 million dollars to developing -- they're they've become partners is that correct.
It we're we're partner would most of the innovative pharmaceutical companies today we have brought in about 950 million to -- about 750.
Million of which.
Have been incredibly non dilutive funding from.
Partners like Roche -- Qaeda Novartis.
I want I want it to sort of even simplify this further it's been described that that if there's a leaky -- meaning to write these genes are coming out of their causing major diseases and problems.
That you don't just come in your therapies don't just come in and mop up the floor they actually plug.
The hole exactly that that Powell during engineered this and how did that come about.
Well you know the central dogma biology DNA makes RNA which that includes proteins and I thought -- clay cassette -- -- that we biology class so proteins in -- bad actors instead of stopping protein from being bad actors we shutter -- what -- says he said is the if you leaky faucet your kitchen today's drugs mop up the floor continuously we shut off the stick it.
Now I just want to let people know that since your IPO which was what back in 2004.
You've outperformed the New York Stock Exchange as arc of Biotech index.
You've gone up a 150%.
The actual index itself was up a 170%.
But it's been a tough 2010 for you -- and I was looking deeper into into the numbers.
And the shorts are circling you like shorts like sharks up 14%.
-- -- float is being shorted.
How do you stay afloat because I've seen stocks small bigger than you have real trouble and in this case.
Well before fortunately as we talked about already because of the significance of the current partners and the opportunity for new partners.
We've raised considerable amount of money have a very -- out how much rate -- position.
We're gonna finish -- -- -- -- over 350 million in cash we -- quarter earnings yesterday with about 400 million cast.
So that's significant runway for the next three or four to take drugs forward and show that they work in a variety of patient setting.
But the Food and Drug Administration approval process is brutal.
And you guys have not yet been approved wind does that happen -- SharePoint on the calendar.
Well our our most advanced program is for respiratory since social viruses we mention which is.
A big issue for kids and people with compromised immune systems lung transplant patients for example were studying -- drug.
So the current trial we have in patients works we could see judge being approved -- to -- to five year time frame as they mentioned I think this very important list.
In Biotech particular company major value creating events will occur as we show that this works in a variety of settings.
Because as Biotech has come before us -- monoclonal antibodies and vaccines.
Want to show works in one setting because we're platform they can work in a variety of settings.
It's very we're watching this ticker symbol de LN YM and I and look at this and I -- this is a company that we need to really continue to watch so when when you get any closer to that approval process let us know we'll certainly look to be back thank Alan and I loved by the way is the center star in the O'Brien constellations very good.
Thank you the president right back at how people watching it all -- thank you very green is the president and CEO.
Filter by section